Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only 40k shares traded. A month ago we would have seen 40k shares traded as a block at 9:30.
It looks like everyone is waiting on the trials to start. Hopefully one will start soon (before end of June).
The week is not over yet. However I would agree we wouldn't see one on the same day of meeting. If so, it would seem very orchestrated.
Somebody thinks share price is going above $0.60 by June 26th
I wonder if the attorney is going to be seated next to Missling as in last year. The lawsuit was still going on so the good doc had to be careful in what he said. Maybe with the lawsuit behind us he will be more open in his expectations. He should since the forward looking speech is given at the onset of the meeting. Let's hope for the best and expect nothing. This should damper the enthusiasm.
Perhaps MJFF may have some input as to the price their patients have to pay since they are funding.
Agreed. They should rename it to Coric procedure. The slow adoption rate is killing share price.
Agreed. If any deal, it won't be until after the SH meeting.
McM - you said "Biogen has a foot in the door..and
that is why Poison Pill Plan.."
If true, I wonder what would be the case if Missling said "No" when Biogen came knocking? If Biogen is making a play on us, I wonder if saying no, would have created a more or less hostile environment? Makes you wonder (be careful what you ask for). :).
Personally, I think it is great having Biogen test 2-73. Do you or anyone know if Biogen also had the approval to test 3-71? Maybe that's why the conference was more heavily fashioned towards 3-71. It was perhaps to highlight our pipeline for other potential suitors.
In regards to MJFF, I believe Biogen is a big donor. If true, then it's kind of ironic that Biogen, indirectly, will be footing the bill on the Parkinson's trial. Hmmm!!!
Perhaps a partner is for 3-71? We should be moving the yard stick with this one. Was Biogen testing only on 2-71 or both?
K9, I hope there is a deal too.
I apologize to everyone for my banter in many of my previous posts. I was pissed there was no 15 month data presented and frustrated we are not moving any faster. It just kills me knowing we have something that would benefit many and no matter how fast we move, it won't be fast enough for our love ones.
Since the vast majority of everyone here believes it's best to vote along with management, I've decided to go back and change my votes to also vote along side with management (and all of you). I'm sure some may doubt my intentions and all I can say is that I am a Christian and in the end, I will be answering to a higher authority so I have ever reason to be truthful here.
I wish all of us well and hopefully we will see this come to fruition real soon.
Regards,
Scott Hunt
Thanks for the offer, you can continue to post. I admit I jumped inappropriately on "bad news" on the 15 month data. Let's just see some news before we have any dilution.
Peace brother.
Ok I'll refrain from saying anything else until after SH meeting.
Makes sense bocce. I wish they wouldn't post abstracts if they are not going to proceed. By posting the abstract sets up expectations (rightly or unjustly). It would have been far better not to.
Good point PK...at least somebody is presenting an good explanation. Thank you.
Presentation on website was after they pulled the abstract? Let's answer that question.
They did announce by the fact of the abstract. They had to know it would become public. It does every time so it's not any different this time. If they intended not to then they shouldn't have raised expectations they would. That is my primary issue. Since they posted the abstract they needed to follow thru for consistency purposes. By pulling it, it leaves the reasons why "all over the place". Was it bad, was it too good to be true, deal/partnership related or perhaps they thought it would be ready and it wasn't. I believe they it would have been better to show what you have and say it was preliminary 15 month data. I tend to lean towards it wasn't as good as they hoped. Until such time it is released, NO ONE really knows why and every' guess is just as good as another.
So all the other companies that don't use kingsdale are using dirty votes? The whole idea of them pushing the vote seems a bit odd and if you take what they are saying (if the reports are true) it seems even more whacky.
Maybe, just maybe, it's a push to get share price up for the next round of dilution since there is no partner and thus we tackle the next phase of AD 100% .
The original intent was to report the 15 month data at this weekend's conference. If not, then why pull the abstract? If hiring kingsdale and pulling the 15 month data was to prevent/hold off a hostile bid, then don't you think the hostile bidder would see these things and advanced their agenda before the SH meeting? Think about it. If there is a hostile bidder, the best way to counter it is to release the data. By releasing data, that is phenomenal, may bring other suitors to the table with better offers.
Call me a basher, shorty or anything else, makes no difference to the truth. The truth is, there is something that doesn't add up. If there is further dilution without any news of PK/PD, or 15 month data or start of other trials or partners then I'm certain many on this board will not be happy. Doing a dilution before the results of Rhett's or Parkinson's will spell disaster. These trials only go for 12 weeks. Surely we have enough cash to cover the trials duration and findings. A diluting at that time will yield better terms. Maybe my unhappiness is a bit premature, however, I can't help to feel what I feel.
Again with the super responders then why haven't we started the next phase already?
I didn't say it wasn't micralous. I said if it is then why haven't we moved more quickly to the next phase? This should have started phase 2/3 months ago
Whatever power. I see the same thing happening here as in nov '15. If you are implying I'm short then I would be relishing in no news. I own 20k+ shares and I'm tired of all the delays. We need to move more quickly.
As I stated in the past I didn't vote for the preferred shares nor the poison pill until I get s reason why we need it. I don't follow Missling blindly. I learned my lesson with ENZ back in 2000. Explain why and then I'll decide.
I'm beginning to get frustrated by lack of progress. A lot of talk over the past year. Now let's see movement
They need to release it. If they are still going over with a fine tooth comb that means they are looking for something good. Didn't they find something good already? Why make tip of iceberg comment. Release ehatvyou have and later if more good comes out of it then pile on the good news. Something smells here.
So what's the holdup in Australia? Govt officials have had to seen the results and the news' stories. I'm shocked they haven't forced accelerated time frames to start the trials. What is the holdup if what we got is so miraculous? People need 2-73 now, not in 2018 or later. Something smells fishy. To be honest I don't like hiring kingsdale at all. It seems very odd.
What ever happen to the discussions of the 21st century cures act. Should that come into play with our AD trials.
It's time for all the rhetoric to stop and time to produce results. Start with the 15 month data.
Skipping 15 and waiting for 18 is a bad idea. It makes the whole trial look random. They need to release 15 and 18. It is what it is. If the reason for the holdup is due to Biogen that should be a cause. An NDA with Biogen should have no bearing on our facts. I could see Biogen wanting to hold theirs up but we shouldn't. To say it's because Biogen doesn't want to compete with higher bids is their problem and we shouldn't run from it.
Then that's wrong. Missling should seek the highest bidder.
Nice list however the buyout numbers can be misleading. Take CPXX for sn example, it shoes JAZZ bought them for s premium of only 73%. I believe they paid $30/ share and the it was around 13 the day before. What it doesn't show, the stock went up from the 2's to the mid teens in the month or so prior to the buyout. So just before approval to actual buyout the stock went from 2 to 30. The same can happen to us from 6 to 90+.
Just because BIIB gets a preview of 2-73 and believes it truly works shouldn't be a reason why we accept their low bid. Maybe that's whats going on behind the scenes and thus the poison pill.
Nice exit package for McNut...in the event of a buyout...they are adding a non CFO to a CFO position...is this a way to pay him his dues in the event of a buyout?
Double talk...if not zero then how many?
"We do not own zero shares of VBIO"
i bet tomorrow or Monday we about the other.
I think so too bourbon. When one hits, it will be time to add to the other, hopefully.
Too bad his comp was awarded 5m shares, when hired, and every six months that pass without some sort of approval his award is reduced .5m shares. Now that would be an incentive!
My two largest holdings (ADXS and AVXL) are both red today while all the other bio's are green.
yes it does and the conclusions (couple slides before) states Diease Modifying Properties.
The question is.....What in the hell are they waiting for? Lets get these started...Stop talking and start doing.
Who was the asian guy sitting next to Missling this morning? Did he meet with him in Japan 2 weeks ago? Just curious.
Also, with the share price down all day, I expect we will close positive for the day. That seems to be the trend - if its up during the day, then we close down and vis-versa.
From the Form 6-K...
It appears they are confident in the approval...
Most importantly, the FDA specified the additional statistical analysis of existing data that would be required to further support the Company’s conclusions. The Company expects that it can provide those data in a compelling fashion and demonstrate that Macrilen™ is a robust, repeatable test, demonstrating adequate sensitivity and specificity and that the performance of the product would be improved by utilizing a more appropriate cut-off point.
Not a bad purchase you are up a penny! :)
Does the EU submission require how the product will be marketed and distributed? We know it includes manufacturing. If it does we can't submit until a partner is in place.
This bucket can't hold any water. It will most likely stay that way until EU approval.
I wonder if it's the docs intent is to start all the 12 week trials concurrently or as close together as possible?